PLI Scheme for Bulk Drugs Draws Rs 5,210 Crore Investment, 39 Projects Commissioned
By RasayanXchange News DeskSource: PSU Watch

PLI Scheme for Bulk Drugs Draws Rs 5,210 Crore Investment, 39 Projects Commissioned

The Department of Pharmaceuticals under the Ministry of Chemicals and Fertilisers reported on September 25, 2026 that the Production Linked Incentive (PLI) Scheme for Bulk Drugs has drawn total investment of Rs 5,210.74 crore as of June 2026, spread across 39 commissioned projects manufacturing 28 active pharmaceutical ingredients (APIs) and key starting materials (KSMs). The scheme, approved in 2020 with a total outlay of Rs 6,940 crore, targets 41 identified critical products where India had historically depended heavily on imports, primarily from China.

Beneficiaries under the scheme have achieved cumulative sales of Rs 3,792.49 crore, including exports worth Rs 560.16 crore, while generating employment for 5,127 people. Notable commissioned projects include Lyfius Pharma (an Aurobindo subsidiary), which invested Rs 2,270.05 crore in a Penicillin-G facility in Andhra Pradesh with 15,000 MT annual capacity; Kinvan Pvt Ltd's Rs 504.68 crore Clavulanic Acid facility in Himachal Pradesh; and Meghmani LLP's Rs 60.46 crore Para amino phenol facility in Gujarat with 13,500 MT capacity.

The government separately highlighted the operationalization of five greenfield projects under the scheme spanning antibiotics, cardiovascular medications, and antipyretics — products where reducing import dependence has been a stated policy priority for several years. For API buyers on RasayanXchange, the scheme's progress signals a gradually deepening base of domestically manufactured fermentation-based and synthetic APIs as an alternative to Chinese imports.

Photo (representative): examining bulk drug containers. U.S. Food and Drug Administration, public domain, via Wikimedia Commons.

Chemicals in this story

View specifications and safety data, or get quotations from suppliers.

Read original source